<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38390796</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>A screening study on the detection strain of Coxsackievirus A6: the key to evaluating neutralizing antibodies in vaccines.</ArticleTitle><Pagination><StartPage>2322671</StartPage><MedlinePgn>2322671</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2322671</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2024.2322671</ELocationID><Abstract><AbstractText>The increasing incidence of diseases caused by Coxsackievirus A6 (CV-A6) and the presence of various mutants in the population present significant public health challenges. Given the concurrent development of multiple vaccines in China, it is challenging to objectively and accurately evaluate the level of neutralizing antibody response to different vaccines. The choice of the detection strain is a crucial factor that influences the detection of neutralizing antibodies. In this study, the National Institutes for Food and Drug Control collected a prototype strain (Gdula), one subgenotype D1, as well as 13 CV-A6 candidate vaccine strains and candidate detection strains (subgenotype D3) from various institutions and manufacturers involved in research and development. We evaluated cross-neutralization activity using plasma from naturally infected adults (<i>n</i> = 30) and serum from rats immunized with the aforementioned CV-A6 strains. Although there were differences between the geometric mean titer (GMT) ranges of human plasma and murine sera, the overall trends were similar. A significant effect of each strain on the neutralizing antibody test (MAX/MIN 48.0 ∼16410.3) was observed. Among all strains, neutralization of the S112 strain by 15 different sera resulted in higher neutralizing antibody titers (GMT<sub>S112 </sub>= 132.0) and more consistent responses across different genotypic immune sera (MAX/MIN = 48.0). Therefore, S112 may serve as a detection strain for NtAb testing in various vaccines, minimizing bias and making it suitable for evaluating the immunogenicity of the CV-A6 vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Yaqian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research &amp; Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingchen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Fangyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Taibang Biologic Group, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zejun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of R&amp;D, Wuhan Institute of Biological Products Co., LTD, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhongping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Production Management, Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhongyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Second Research Laboratory, National Vaccine and Serum Institute, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Meirong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>R&amp;D Center, Minhai Biotechnology Co., LTD, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yingzhi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>R&amp;D Center, Minhai Biotechnology Co., LTD, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yajing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>R&amp;D Center, Sinovac Biotech Co., LTD, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1638-6214</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A6</Keyword><Keyword MajorTopicYN="N">cross-neutralization</Keyword><Keyword MajorTopicYN="N">cross-protection</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38390796</ArticleId><ArticleId IdType="pmc">PMC10906128</ArticleId><ArticleId IdType="doi">10.1080/22221751.2024.2322671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Repass GL, Palmer WC, Stancamplano FF.. Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Cleve Clin J Med. 2014;81(9):537–543. doi: 10.3949/ccjm.81a.13132</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.81a.13132</ArticleId><ArticleId IdType="pubmed">25183845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Cohen R, Bisseux M, et al. . A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 2021;26(43):2100978. doi: 10.2807/1560-7917.ES.2021.26.43.2100978</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.43.2100978</ArticleId><ArticleId IdType="pmc">PMC8555367</ArticleId><ArticleId IdType="pubmed">34713796</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona RCC, Machado BC, Reis FC, et al. . Hand, foot, and mouth disease outbreak by Coxsackievirus A6 during COVID-19 pandemic in 2021, São Paulo, Brazil. J Clin Virol. 2022;154:105245. doi: 10.1016/j.jcv.2022.105245</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105245</ArticleId><ArticleId IdType="pmc">PMC9301960</ArticleId><ArticleId IdType="pubmed">35896051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanbayashi D, Kaida A, Hirai Y, et al. . An epidemic of hand, foot, and mouth disease caused by coxsackievirus A6 in Osaka city, Japan, in 2017. Jpn J Infect Dis. 2019;72(5):334–336. doi:10.7883/yoken.JJID.2018.532</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2018.532</ArticleId><ArticleId IdType="pubmed">31061358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MHP, Chong YM, Tay CG, et al. . Detection of enteroviruses during a 2018 hand, foot and mouth disease outbreak in Malaysia. Trop Biomed. 2021;38(1):150–153. doi: 10.47665/tb.38.1.026</Citation><ArticleIdList><ArticleId IdType="doi">10.47665/tb.38.1.026</ArticleId><ArticleId IdType="pubmed">33797539</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan LNT, Khanh TH, Hong NTT, et al. . Clinical, etiological and epidemiological investigations of hand, foot and mouth disease in southern Vietnam during 2015 – 2018. PLoSNegl Trop Dis. 2020;14(8):e0008544. doi: 10.1371/journal.pntd.0008544</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008544</ArticleId><ArticleId IdType="pmc">PMC7451980</ArticleId><ArticleId IdType="pubmed">32804980</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu SS, Li HJ, Qiao P, et al. . Neonatal hand, foot, and mouth disease due to coxsackievirus A6 in Shanghai. BMC Pediatr. 2020;20(1):364. doi: 10.1186/s12887-020-02262-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-020-02262-y</ArticleId><ArticleId IdType="pmc">PMC7397588</ArticleId><ArticleId IdType="pubmed">32741368</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MC, Sarmiento L, Resik S, et al. . Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011-2013. Arch Virol. 2014;159(9):2451–2455. doi: 10.1007/s00705-014-2071-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-014-2071-x</ArticleId><ArticleId IdType="pubmed">24719197</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Chieochansin T, Linsuwanon P, et al. . Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012, Thailand, 2013. Emerg Infect Dis. 2013;19(4):641–643. doi: 10.3201/eid1904.121666</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Henquell C, Archimbaud C, et al. . Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012;18(5):E110–E118. doi: 10.1111/j.1469-0691.2012.03789.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair C, Gaunt E, Simmonds P, et al. . Atypical hand, foot, and mouth disease associated with coxsackievirus A6 infection, Edinburgh, United Kingdom, January to February 2014. Euro Surveill. 2014;19(12):20745. doi: 10.2807/1560-7917.es2014.19.12.20745</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es2014.19.12.20745</ArticleId><ArticleId IdType="pubmed">24698138</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsten HH, Kemp M, Fischer TK, et al. . Atypical Hand, Foot, and mouth disease caused by coxsackievirus A6 in Denmark: A diagnostic mimicker. Acta DermVenereol. 2018;98(3):350–354. doi: 10.2340/00015555-2853</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-2853</ArticleId><ArticleId IdType="pubmed">29182793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisterna DM, Lema CL, Martinez LM, et al. . Atypical hand, foot, and mouth disease caused by Coxsackievirus A6 in Argentina in 2015. Rev Argent Microbiol. 2019;51(2):140–143. doi: 10.1016/j.ram.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ram.2018.05.003</ArticleId><ArticleId IdType="pubmed">30269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri I, Dondi A, Wollenberg A, et al. . Atypical forms of hand, foot, and mouth disease: A prospective study of 47 Italian children. Pediatr Dermatol. 2016;33(4):429–437. doi: 10.1111/pde.12871</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.12871</ArticleId><ArticleId IdType="pubmed">27292085</ArticleId></ArticleIdList></Reference><Reference><Citation>Justino MCA, Mesquita DS, Souza MF, et al. . Atypical hand-foot-mouth disease in Belém, Amazon region, northern Brazil, with detection of coxsackievirus A6. J Clin Virol. 2020;126:104307. doi: 10.1016/j.jcv.2020.104307</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104307</ArticleId><ArticleId IdType="pubmed">32302950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayman R, Shepherd M, Tarring C, et al. . Outbreak of variant hand-foot-and-mouth disease caused by coxsackievirus A6 in Auckland, New Zealand. Paediatr Child Health. Paediatr Child Health. 2014;50(10):751–755. doi: 10.1111/jpc.12708</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpc.12708</ArticleId><ArticleId IdType="pubmed">25123330</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YN, Xiong TT, Meng Y, et al. . Risk factors for severe hand, foot, and mouth disease infected with Coxsackievirus A6: A hospital-based case-control study. J Med Virol. 2020;3144–3150. doi: 10.1002/jmv.26343</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26343</ArticleId><ArticleId IdType="pubmed">32706451</ArticleId></ArticleIdList></Reference><Reference><Citation>Du ZQ, Zhao YL, Luo YJ, et al. . Ongoing change of severe hand, foot, and mouth disease pathogens in Yunnan, China, 2012 to 2016. J Med Virol. 2019;91(5):881–885. doi: 10.1002/jmv.25393</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25393</ArticleId><ArticleId IdType="pubmed">30613995</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchs A, Azevedo LS, Souza EV, et al. . Coxsackievirus A6 strains causing an outbreak of hand-foot-and-mouth disease in Northeastern Brazil in 2018. Rev Inst Med Trop Sao Paulo. 2022;64:e16. doi: 10.1590/s1678-9946202264016</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1678-9946202264016</ArticleId><ArticleId IdType="pmc">PMC8862545</ArticleId><ArticleId IdType="pubmed">35195198</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep. 2012;61(12):213–214.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetrit EB, Well YW, Shulman LM, et al. . Coxsackievirus A6-related hand foot and mouth disease: skin manifestations in a cluster of adult patients. J Clin Virol. 2014;59(3):201–203. doi: 10.1016/j.jcv.2013.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2013.12.012</ArticleId><ArticleId IdType="pubmed">24457116</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CCY, Lau SKP, Woo PCY, et al. . Human enterovirus 71 epidemics: what's next?. Emerg Health Threats J. 2013;6:19780. doi: 10.3402/ehtj.v6i0.19780</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Sumi A, Toyoda S, et al. . Time series analysis of reported cases of hand, foot, and mouth disease from 2010 to 2013 in Wuhan, China. BMC Infect Dis. 2015;15:495. doi: 10.1186/s12879-015-1233-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1233-0</ArticleId><ArticleId IdType="pmc">PMC4630926</ArticleId><ArticleId IdType="pubmed">26530702</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Saengdao N, Khanarat N, et al. . Evolutionary and genetic recombination analyses of coxsackievirus A6 variants associated with hand, foot, and mouth disease outbreaks in Thailand between 2019 and 2022. Viruses. 2023;15(1):73. doi: 10.3390/v15010073</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010073</ArticleId><ArticleId IdType="pmc">PMC9863931</ArticleId><ArticleId IdType="pubmed">36680113</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitomi H, Ashizuka Y, Ichihara S, et al. . Molecular epidemiology of coxsackievirus A6 derived from hand, foot, and mouth disease in Fukuoka between 2013 and 2017. J Med Virol. 2018;90(11):1712–1719. doi: 10.1002/jmv.25250</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25250</ArticleId><ArticleId IdType="pubmed">29981169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanbayashi D, Kaida A, Hirai Y, et al. . An epidemic of hand, foot, and mouth disease caused by coxsackievirus A6 in Osaka city, Japan, in 2017. Jpn J Infect Dis. 2019;72(5):334–336. doi: 10.7883/yoken.JJID.2018.532</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2018.532</ArticleId><ArticleId IdType="pubmed">31061358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjay RE, Josmi J, Sasidharanpillai S, et al. . Molecular epidemiology of enteroviruses associated with hand, foot, and mouth disease in South India from 2015 to 2017. Arch Virol. 2022;167(11):2229–2238. doi: 10.1007/s00705-022-05561-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-022-05561-0</ArticleId><ArticleId IdType="pmc">PMC9377658</ArticleId><ArticleId IdType="pubmed">35970888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SH, Huang YP, Liu MC, et al. . An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346. doi: 10.1186/1471-2334-11-346</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-11-346</ArticleId><ArticleId IdType="pmc">PMC3297538</ArticleId><ArticleId IdType="pubmed">22168544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong SB, Wang XL, Huo D, et al. . Epidemiological characteristics of hand, foot and mouth disease among people aged 6 and over in Beijing, 2011-2020. Zhonghua Liu Xing Bing Xue Za Zhi. 2022;43(2):207–212. doi: 10.3760/cma.j.cn112338-20210511-00387</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112338-20210511-00387</ArticleId><ArticleId IdType="pubmed">35184486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Teng Z, Cui XQ, et al. . Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012–2016, People’s Republic of China, 2018. Emerg Microbes Infect. 2018;7(1):1. doi: 10.1038/s41426-017-0011-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0011-z</ArticleId><ArticleId IdType="pmc">PMC5837173</ArticleId><ArticleId IdType="pubmed">29362406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Zeng H, Zheng H, et al. . Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic. Clin Microbiol Infect. 2014;20(7):O442–O445. doi: 10.1111/1469-0691.12468</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12468</ArticleId><ArticleId IdType="pubmed">24428125</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JL, Yuan J, Yang F, et al. . Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect. 2014;69(3):299–303. doi: 10.1016/j.jinf.2014.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.04.001</ArticleId><ArticleId IdType="pubmed">24731881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu HY, Ma CJ, Yang QZ, et al. . Hand, foot and mouth disease caused By coxsackievirus A6, Beijing, 2013. Pediatr Infect Dis J. 2014;33(12):1302–1303. doi: 10.1097/INF.0000000000000467</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000467</ArticleId><ArticleId IdType="pubmed">25037037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan XJ, Li L, Zhang BM, et al. . Molecular epidemiology of coxsackievirus A6 associated with outbreaks of hand, foot, and mouth disease in Tianjin, China, in 2013. Arch Virol. 2015;160(4):1097–1104. doi: 10.1007/s00705-015-2340-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-015-2340-3</ArticleId><ArticleId IdType="pmc">PMC4629805</ArticleId><ArticleId IdType="pubmed">25680566</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Xu S, Zhang Y, et al. . Hand, foot and mouth disease outbreak caused by coxsackievirus A6, China 2013. J Infect. 2014;69(3):303–305. doi: 10.1016/j.jinf.2014.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.03.015</ArticleId><ArticleId IdType="pubmed">24704297</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JJ, Pan H, Wang XS, et al. . Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine. Emerg Microbes Infect. 2018;7(1):1–7. doi: 10.1038/s41426-018-0035-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0035-z</ArticleId><ArticleId IdType="pmc">PMC5861114</ArticleId><ArticleId IdType="pubmed">29559626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Yang YN, Zheng RR, et al. . Epidemiological characteristics of hand, foot, and mouth disease clusters during 2016-2020 in Beijing, China. J Med Virol. 2022;94(10):4934–4943. doi: 10.1002/jmv.27906</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27906</ArticleId><ArticleId IdType="pubmed">35655366</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan XX, Zhang CY, Wang X, et al. . Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in Chengdu, People’s Republic of China, 2017-2022: a descriptive study. Emerg Microbes Infect. 2022;11(1):2510–2519. doi: 10.1080/22221751.2022.2125346</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2125346</ArticleId><ArticleId IdType="pmc">PMC9621254</ArticleId><ArticleId IdType="pubmed">36103331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M, Tarragó D, Almagro CM, et al. . Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain. Clin Microbiol Infect. 2014;20(3):O150–O156. doi: 10.1111/1469-0691.12361</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12361</ArticleId><ArticleId IdType="pubmed">24033818</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrés C, Guasch E, Piñana M, et al. . Recombinant CV-A6 strains related to hand-foot-mouth disease and herpangina at primary care centers (Barcelona, Spain). Future Microbiol. 2019;14:499–507. doi: 10.2217/fmb-2018-0336</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2018-0336</ArticleId><ArticleId IdType="pubmed">31033351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bujaki E, Farkas A, Rigó Z, et al. . Distribution of enterovirus genotypes detected in clinical samples in Hungary, 2010-2018. Acta Microbiol Immunol Hung. 2020;67(4):201–208. doi: 10.1556/030.2020.01200</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/030.2020.01200</ArticleId><ArticleId IdType="pubmed">33295885</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ji H, Shen WQ, et al. . Disease burden in patients with severe hand, foot, and mouth disease in Jiangsu Province: a cross-sectional study. Hum Vaccin Immunother. 2022;18(5):2049168. doi: 10.1080/21645515.2022.2049168</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2049168</ArticleId><ArticleId IdType="pmc">PMC9196847</ArticleId><ArticleId IdType="pubmed">35476031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang YP, Bian LL, et al. . EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606. doi: 10.1586/14760584.2016.1138862</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang YP, Bian LL, et al. . EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):1. doi: 10.1038/emi.2016.73</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Shen CY, Zhang C, et al. . Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165–169. doi: 10.1016/j.antiviral.2016.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.06.004</ArticleId><ArticleId IdType="pubmed">27315772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Wang Q, et al. . Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095–7104. doi: 10.1016/j.vaccine.2018.09.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Fuchs J, Das SC, et al. . Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7:5919–5932. doi: 10.3390/v7112916</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Rung S, et al. . Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016:129:58–66. doi: 10.1016/j.antiviral.2016.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H, Ln HJ, Lee JA, et al. . The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36(24):3445–3452. doi: 10.1016/j.vaccine.2018.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai WL, Zhang C, et al. . A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):1. doi: 10.1038/s41426-018-0094-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Yuan YD, Cui BP, et al. . Cross-Antigenicity between EV71 Sub-genotypes: implications for vaccine efficacy. Viruses. 2021;13(5):720. doi: 10.3390/v13050720</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050720</ArticleId><ArticleId IdType="pmc">PMC8143144</ArticleId><ArticleId IdType="pubmed">33919184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu WB, Jin PF, Li JX, et al. . Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Review of Vaccines.2017;16(9): 945–949. doi: 10.1080/14760584.2017.1335603</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1335603</ArticleId><ArticleId IdType="pubmed">28548626</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M, Chong P.. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum Vaccin Immunother. 2015;11(11):2688–2704. doi: 10.1080/21645515.2015.1049780</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1049780</ArticleId><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Gao F, Wang YM, et al. . Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial. Lancet Reg Health West Pac. 2021;16:100284. doi: 10.1016/j.lanwpc.2021.100284</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100284</ArticleId><ArticleId IdType="pmc">PMC8579145</ArticleId><ArticleId IdType="pubmed">34881371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Xu WB, Xia JL, et al. . Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo YQ, Yang JH, Liu P, et al. . Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains. Hum Vaccin Immunother. 2024;17(12):5334–5347. doi: 10.1080/21645515.2021.1978792</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1978792</ArticleId><ArticleId IdType="pmc">PMC8903991</ArticleId><ArticleId IdType="pubmed">34756160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5(2):85–86. doi: 10.5501/wjv.v5.i2.85</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v5.i2.85</ArticleId><ArticleId IdType="pmc">PMC4861875</ArticleId><ArticleId IdType="pubmed">27175354</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Zhang Y, Ji TJ, et al. . Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci Rep. 2017;7(1):5491. doi: 10.1038/s41598-017-05618-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05618-0</ArticleId><ArticleId IdType="pmc">PMC5511160</ArticleId><ArticleId IdType="pubmed">28710474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu PY, Ji WQ, Li D, et al. . Current status of hand-foot-and-mouth disease. J Biomed Sci. 2023;30(1):15. doi: 10.1186/s12929-023-00908-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00908-4</ArticleId><ArticleId IdType="pmc">PMC9951172</ArticleId><ArticleId IdType="pubmed">36829162</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalldorf G. The coxsackievirus group. AnnN Y Acad Sci 1953;56(3):583–586. doi: 10.1111/j.1749-6632.1953.tb30251.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1953.tb30251.x</ArticleId><ArticleId IdType="pubmed">13139263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu XM, Wan ZZ, Li YP, et al. . National epidemiology and evolutionary history of four hand, foot and mouth disease-related enteroviruses in China from 2008 to 2016. Virol Sin. 2020;35(1):21–33. doi: 10.1007/s12250-019-00169-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-019-00169-2</ArticleId><ArticleId IdType="pmc">PMC7035399</ArticleId><ArticleId IdType="pubmed">31664644</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JH, Zhang C, Zhou Y, et al. . A 3.0-angstrom resolution cryo-electron microscopy structure and antigenic sites of coxsackievirus A6-like particles. J Virol. 2018;92(2):e01257. doi: 10.1128/JVI.01257-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01257-17</ArticleId><ArticleId IdType="pmc">PMC5752931</ArticleId><ArticleId IdType="pubmed">29093091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, Yu H, Hong QY, et al. . Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8(1):505. doi: 10.1038/s41467-017-00477-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00477-9</ArticleId><ArticleId IdType="pmc">PMC5593947</ArticleId><ArticleId IdType="pubmed">28894095</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Recommendations to assure the quality, safety and 6 efficacy of Enterovirus 71 vaccines (inactivated).[cited 2023 Oct 10]. Available from: https://www.who.int/news-room/articles-detail/call-for-comments-on-ev71-recommendations.</Citation></Reference><Reference><Citation>Lei DL, Griffiths E, Martin J.. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine. 2020;38(32):4917–4923. doi: 10.1016/j.vaccine.2020.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7327506</ArticleId><ArticleId IdType="pubmed">32418797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Li N, Yu X, et al. . Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):37–41. doi: 10.1007/s00705-011-1136-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1136-3</ArticleId><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmgren L, Li XG, Wilson C, et al. . A global regulatory science agenda for vaccines. Vaccine. 2013;31(Suppl):B163–B175. doi: 10.1016/j.vaccine.2012.10.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.117</ArticleId><ArticleId IdType="pubmed">23598478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>